DCOYDecoy Therapeutics Inc. Common Stock

3.200USD-6.16%Mkt Cap: 2.10M $P/E: 0.03

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (I…

Key Statistics

Company
Market Cap2.10M $
Enterprise Value-6.14M $
Revenue (TTM)227.63K $
Gross Profit-1.63M $
Net Income (TTM)-12.52M $
Revenue/Share0.6360 USD
Last Price3.200 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)0.03
P/E (Forward)-0.17
PEG
EV/EBITDA1.01
EV/Revenue-26.97
P/S9.44
P/B0.30
EPS (TTM)113.26
EPS (Forward)-19.32
52W Range
3.1700% of range85.20
52W High85.20 USD
52W Low3.170 USD
Profitability
Gross Margin0.00%
Oper. Margin-1055.84%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-212.58%
ROA-113.22%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-4.83M $
CapEx (TTM)577.00K $
FCF Margin-224.00%
FCF Yield-24.32%
Net Debt-8.29M $
Net Debt/EBITDA1.36
Balance Sheet
Debt/Equity
Current Ratio1.83
Quick Ratio1.77
Book Value/Sh11.07 USD
Cash/Share12.65 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split1:12
Split DateMar 9, 2026
Analyst Consensus
Rating
Target (Mean)
Target Range
# Analysts
Ownership
Shares Out.655.18K
Float651.35K
Insiders0.47%
Institutions9.67%
Short Interest
Short Ratio0.3d
Short % Float4.77%
Short % Out.4.75%
Shares Short25.25K
Short (prev mo.)156.31K
Technical
SMA 505.256 (-39.1%)
SMA 2008.164 (-60.8%)
Beta0.58
S&P 52W Chg18.16%
Avg Vol (30d)58.05K
Avg Vol (10d)23.95K
Technical Indicators
RSI (14)30.1
MACD-0.5987
MACD Signal-0.5927
MACD Hist.-0.0060
BB Upper5.040 USD
BB Middle4.007 USD
BB Lower2.974 USD
BB Width51.57%
ATR (14)0.5166 USD
Vol Ratio (20d)0.19x